Key statistics
As of last trade Renovaro Inc (2Q5:DEU) traded at 0.378, 9.57% above its 52-week low of 0.345, set on Oct 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3725 |
---|---|
High | 0.412 |
Low | 0.352 |
Bid | 0.364 |
Offer | 0.3885 |
Previous close | 0.392 |
Average volume | 800.00 |
---|---|
Shares outstanding | 147.50m |
Free float | 110.70m |
P/E (TTM) | -- |
Market cap | 60.85m USD |
EPS (TTM) | -1.08 USD |
Data delayed at least 15 minutes, as of Oct 08 2024.
More ▼
Announcements
- PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
- Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
- RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
- RenovaroCube Announces Strategic Offering of Up to 20% Ownership
- Renovaro, Inc. Announces $10 million in Equity Committed
- Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
- Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
- RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
- Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
- Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
More ▼